Evidence map›Paper›PMID 41342940›Full record

ArticleSurgery today2026

Survival outcomes of alectinib in postoperative recurrent ALK-rearranged lung cancer.

Ryo Miyata, Masatsugu Hamaji, Hiroyuki Kurakami, Ryo Nakanobo, Masashi Kobayashi, Ryota Sumitomo, Masaka Ikeda, Masashi Ishikawa, Takehisa Fukada, Hiroaki Sakai and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ryo MiyataDepartment of Thoracic and Cardiovascular Surgery, Nara Medical University, Nara, Japan. rmiyata@kuhp.kyoto-u.ac.jp.ORCID http://orcid.org/0000-0002-8306-4856
Masatsugu HamajiDepartment of Thoracic and Cardiovascular Surgery, Nara Medical University, Nara, Japan.
Hiroyuki KurakamiInstitute for Clinical and Translational Science, Nara Medical University, Nare, Japan.
Ryo NakanoboDepartment of Thoracic Surgery, Kurashiki Central Hospital, Okayama, Japan.
Masashi KobayashiDepartment of Thoracic Surgery, Kurashiki Central Hospital, Okayama, Japan.
Ryota SumitomoDepartment of Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan.
Masaka IkedaDepartment of Thoracic Surgery, Red Cross Wakayama Medical Center, Wakayama, Japan.
Masashi IshikawaDepartment of Thoracic Surgery, Red Cross Wakayama Medical Center, Wakayama, Japan.
Takehisa FukadaDepartment of Thoracic Surgery, Hyogo Prefectural Amagasaki General Medical Center, Hyogo, Japan.
Hiroaki SakaiDepartment of Thoracic Surgery, Hyogo Prefectural Amagasaki General Medical Center, Hyogo, Japan.
Hiromi OdaDepartment of Thoracic Surgery, Kitano Hospital, The Tazuke Kofukai Medical Institute, Osaka, Japan.
Akihiro OhsumiDepartment of Thoracic Surgery, Kitano Hospital, The Tazuke Kofukai Medical Institute, Osaka, Japan.
Tetsuji MoriyaDepartment of Chest Surgery, Red Cross Fukui Hospital, Fukui, Japan.
Hiroya YamagishiDepartment of Chest Surgery, Red Cross Fukui Hospital, Fukui, Japan.
Hiroshi DateDepartment of Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The clinical benefits of anaplastic lymphoma kinase (ALK) inhibitors in patients with recurrent ALK-rearranged lung adenocarcinoma after surgical resection remain poorly understood. We retrospectively reviewed the medical records of 10 patients who received alectinib as first-line therapy for postoperative recurrence between 2014 and 2018, following complete resection at multiple institutions in Japan. Clinical outcomes, including the progression-free survival (PFS) and overall survival (OS), were analyzed. The median follow-up duration was 93.6 months from surgery. The median OS was 96.8 months after surgery and 82.8 months from recurrence. The median PFS from recurrence was not reached, with a 5-year PFS rate of 58.3%. One patient discontinued treatment because of adverse events. Alectinib, as a first-line therapy for recurrent ALK-rearranged lung adenocarcinoma, demonstrated durable efficacy and acceptable safety. These findings suggest that targeted therapy for recurrence is a valuable treatment strategy. Prospective studies are warranted to determine the optimal timing for ALK-TKI initiation.

Indexed as

Adenocarcinoma of LungAnaplastic Lymphoma KinaseCarbazolesGene RearrangementLung NeoplasmsMolecular Targeted TherapyNeoplasm Recurrence, LocalPiperidinesProtein Kinase InhibitorsAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedPostoperative PeriodalectinibALK protein, humanAnaplastic Lymphoma KinaseCarbazolesPiperidinesProtein Kinase InhibitorsAlectinibALK-rearranged lung cancerNon-small-cell lung cancerPostoperative recurrenceTargeted therapy

Identifiers

PMID41342940

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.